MESENCHYMAL STEM CELLS AS AN ATTRACTIVE CANDIDATE FOR EX–VIVO GENE TRANSFER AND REGENERATIVE CELL THERAPY

Ajinkya Inamdar; Amol Gaikwad; Jayashri Mali; Suvarna Patil; Arati Inamdar

Volume : IX, Issue : IV, April - 2019

MESENCHYMAL STEM CELLS AS AN ATTRACTIVE CANDIDATE FOR EX–VIVO GENE TRANSFER AND REGENERATIVE CELL THERAPY

Ajinkya Inamdar, Amol Gaikwad, Jayashri Mali, Suvarna Patil, Arati Inamdar

Abstract :

Mesenchymal stem cells (MSCs) possess exceptional abilities of HLA independent universal acceptance, tumor tropism, immunomodulation, ability to be available off–the shelf and flexibility of expression of transgenic proteins whenever desired. MSCs also secrete regenerative and anti–inflammatory factors and MSC–secretome is one of the highly studied emerging therapeutic agents which has led to utilization of conditioned media as a therapeutic agent. MSCs have been studied for the treatment of neurological diseases, cardiovascular ailments, immunological diseases, metabolic disorders and metastatic cancers. It is important to look at the decade long journey of MSCs as therapeutic agents so that the future directions can be confirmed. Takeda pharmaceutical company (after acquisition of TiGenixInc) has successfully received approval in Europe for its first mesenchymal stem cell therapy Alofisel® for the treatment of complex perianal fistulas in Crohn’s disease. Mesenchymal stem cells also offer one of the best platforms for the administration of ex–vivo gene therapy as well as exceptional opportunities for development of multifaceted cell therapies for multiple diseases. In this review article, we have attempted to provide a bird’s eye view of overall development of MSCs as a therapeutic approach for various diseases including cancer.